Download PDF
Semin Neurol 2015; 35(04): 398-406
DOI: 10.1055/s-0035-1558974
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Acquired Immunologic Neuropathies

Jeffrey A. Allen
1   Department of Neurology, University of Minnesota, Minneapolis, Minnesota
2   Department of Neurology, Northwestern University, Chicago, Illinois
,
Gareth J. Parry
1   Department of Neurology, University of Minnesota, Minneapolis, Minnesota
› Author Affiliations
Further Information

Publication History

Publication Date:
06 October 2015 (online)

    Permissions and Reprints

Abstract

The acquired immunologic neuropathies are a collection of neuropathic conditions that result from abnormal immune responses that target peripheral nerve myelin, Schwann cells, or axons. Although the clinical features and diagnostic data are sometimes overlapping, the specific disorders are heterogeneous in pathogenesis, treatment, and prognosis. Importantly, there is no consensus as to which neuropathies are distinct conditions and which are better considered as variants or subtypes. The authors discuss the clinical, electrophysiological, histopathological, and treatment features that define the acquired immunomediated neuropathies, calling attention to differences that are observed between the specific neuropathies as well as the differences in the presumed variants within each syndrome.

Keywords

inflammatory - immunological - immunomediated - Guillain-Barré syndrome - chronic inflammatory demyelinating polyneuropathy - neuropathy - multifocal motor neuropathy - Lewis-Sumner syndrome
 

  • References

  • 1 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32 (2) 150-163
    CrossrefPubMedGoogle Scholar
  • 2 Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326 (17) 1130-1136
    CrossrefPubMedGoogle Scholar
  • 3 Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014; 137 (Pt 1): 33-43
    CrossrefPubMedGoogle Scholar
  • 4 Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64 (1) 74-77
    CrossrefPubMedGoogle Scholar
  • 5 González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol 2013; 13: 95
    CrossrefPubMedGoogle Scholar
  • 6 Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol 2013; 12 (12) 1180-1188
    CrossrefPubMedGoogle Scholar
  • 7 Wu X, Wu W, Wang Z , et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China. PLoS ONE 2014; 9 (8) e104074
    CrossrefPubMedGoogle Scholar
  • 8 Hiraga A, Mori M, Ogawara K , et al. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2005; 76 (5) 719-722
    CrossrefPubMedGoogle Scholar
  • 9 Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T. Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Neurology 1998; 51 (6) 1656-1660
    CrossrefPubMedGoogle Scholar
  • 10 Griffin JW, Li CY, Ho TW , et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39 (1) 17-28
    CrossrefPubMedGoogle Scholar
  • 11 Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta 2015; 1852 (4) 658-666
    CrossrefPubMedGoogle Scholar
  • 12 Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome. Philadelphia, PA: F.A. Davis; 1991
    Google Scholar
  • 13 Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56 (8) 1104-1106
    CrossrefPubMedGoogle Scholar
  • 14 Van den Bergh PY, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004; 29 (4) 565-574
    CrossrefPubMedGoogle Scholar
  • 15 Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: an update. J Clin Neurosci 2009; 16 (6) 733-741
    CrossrefPubMedGoogle Scholar
  • 16 The Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology 1985; 35 (8) 1096-1104
    CrossrefPubMedGoogle Scholar
  • 17 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; 9: CD002063
    PubMedGoogle Scholar
  • 18 Hadden RD, Cornblath DR, Hughes RAC , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44 (5) 780-788
    CrossrefPubMedGoogle Scholar
  • 19 Visser LH, Van der Meché FG, Van Doorn PA , et al; Dutch Guillain-Barré Study Group. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995; 118 (Pt 4) 841-847
    CrossrefPubMedGoogle Scholar
  • 20 Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66 (5) 677-680
    CrossrefPubMedGoogle Scholar
  • 21 Van den Bergh PY, Hadden RD, Bouche P , et al; European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010; 17 (3) 356-363
    CrossrefPubMedGoogle Scholar
  • 22 Jung S, Gaupp S, Korn T, Köllner G, Hartung HP, Toyka KV. Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization. J Neurosci Res 2004; 75 (4) 524-535
    CrossrefPubMedGoogle Scholar
  • 23 Berger M, Allen JA. Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach. Muscle Nerve 2015; 51 (3) 315-326
    CrossrefPubMedGoogle Scholar
  • 24 Attarian S, Verschueren A, Franques J, Salort-Campana E, Jouve E, Pouget J. Response to treatment in patients with Lewis-Sumner syndrome. Muscle Nerve 2011; 44 (2) 179-184
    CrossrefPubMedGoogle Scholar
  • 25 Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54 (3) 615-620
    CrossrefPubMedGoogle Scholar
  • 26 Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32 (9) 958-964
    CrossrefPubMedGoogle Scholar
  • 27 Rajabally YA, Wong SL. Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology. J Clin Neuromuscul Dis 2012; 13 (3) 149-152
    CrossrefPubMedGoogle Scholar
  • 28 Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004; 63 (9) 1662-1669
    CrossrefPubMedGoogle Scholar
  • 29 Cornblath DR, Gorson KC, Hughes RA, Merkies IS. Observations on chronic inflammatory demyelinating polyneuropathy: a plea for a rigorous approach to diagnosis and treatment. J Neurol Sci 2013; 330 (1–2) 2-3
    CrossrefPubMedGoogle Scholar
  • 30 Allen JA, Lewis RA. CIDP diagnostic pit-falls and perception of treatment benefit. Neurology 2015 Jul 15. [Epub ahead of print]
    PubMedGoogle Scholar
  • 31 Cocito D, Paolasso I, Antonini G , et al; Italian Network for CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17 (2) 289-294
    CrossrefPubMedGoogle Scholar
  • 32 Nobile-Orazio E, Cocito D, Jann S , et al; IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11 (6) 493-502
    CrossrefPubMedGoogle Scholar
  • 33 Nobile-Orazio E, Cocito D, Jann S , et al. Frequency and time to relapse after therapy discontinuation in CIDP patients treated for six months with IVIg or IV methylprednisolone (IMC follow-up study. J Neurol Neurosurg Psychiatry 2015; 86 (7) 729-734
    CrossrefPubMedGoogle Scholar
  • 34 Hughes RA, Donofrio P, Bril V , et al; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7 (2) 136-144
    CrossrefPubMedGoogle Scholar
  • 35 Mahdi-Rogers M, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013; 6: CD003280
    PubMedGoogle Scholar
  • 36 Parry GJ, Clarke S. Pure motor neuropathy with multifocal conduction block masquerading as motor neuron disease. Muscle Nerve 1988; 11 (2) 103-107
    CrossrefPubMedGoogle Scholar
  • 37 Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001; 115 (1–2) 4-18
    CrossrefPubMedGoogle Scholar
  • 38 Cats EA, Jacobs BC, Yuki N , et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 2010; 75 (22) 1961-1967
    CrossrefPubMedGoogle Scholar
  • 39 Yuki N, Watanabe H, Nakajima T, Späth PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011; 82 (1) 87-91
    CrossrefPubMedGoogle Scholar
  • 40 Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 2010; 15 (4) 295-301
    CrossrefPubMedGoogle Scholar
  • 41 van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005; (2) CD004429
    PubMedGoogle Scholar
  • 42 Van den Berg-Vos RM, Franssen H, Visser J , et al. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J Neurol 2002; 249 (3) 330-336
    CrossrefPubMedGoogle Scholar
  • 43 Chaudhry V, Cornblath DR. An open-label trial of rituximab (Rituxan) in multifocal motor neuropathy (MMN). J Peripher Nerv Syst 2010; 15 (3) 196-201
    CrossrefPubMedGoogle Scholar
  • 44 Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 1993; 114 (2) 193-199
    CrossrefPubMedGoogle Scholar
  • 45 Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86 (7) 591-601
    CrossrefPubMedGoogle Scholar
  • 46 Mauermann ML, Sorenson EJ, Dispenzieri A , et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. J Neurol Neurosurg Psychiatry 2012; 83 (5) 480-486
    CrossrefPubMedGoogle Scholar
  • 47 Dispenzieri A, Kyle RA, Lacy MQ , et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101 (7) 2496-2506
    CrossrefPubMedGoogle Scholar
  • 48 Nobile-Orazio E, Manfredini E, Carpo M , et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36 (3) 416-424
    CrossrefPubMedGoogle Scholar
  • 49 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000; 123 (Pt 4) 710-717
    CrossrefPubMedGoogle Scholar
  • 50 Dalakas MC, Rakocevic G, Salajegheh M , et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009; 65 (3) 286-293
    CrossrefPubMedGoogle Scholar
  • 51 Léger JM, Viala K, Nicolas G , et al; RIMAG Study Group (France and Switzerland). Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013; 80 (24) 2217-2225
    CrossrefPubMedGoogle Scholar